Konruns(603590)2023-08-02 10:37Financial Performance - "Su Ling" sales increased by 48.94% year-on-year in the first half of the year [3] - "Mi Gai Xi" sales revenue reached 134 million yuan in the first half, a slight decrease of 1.7% year-on-year [4] Market and Product Strategy - "Su Ling" benefited from national medical insurance renewal and restrictions lifting, with increased terminal coverage and academic activities [2] - "Su Ling" lifecycle management and pharmacoeconomic research continue to enhance product value [3] - "Mi Gai Xi" maintains a leading position in osteoporosis and acute bone loss treatment, with strong academic and clinical recognition [3] - Local centralized procurement in Zhejiang has minimal impact on "Mi Gai Xi" sales, accounting for only 8%-9% of total revenue [4] R&D and Clinical Progress - KC1036, a multi-target receptor tyrosine kinase inhibitor, has shown significant clinical efficacy in various solid tumors with over 100 cases enrolled [4] - Jin Cao Pian, a traditional Chinese medicine for chronic pelvic pain, is progressing well in Phase III clinical trials with over half of the 414 planned enrollments completed [4] - KC-B173, a recombinant human coagulation factor VIIa project, is advancing in preclinical studies with potential clinical benefits [5] Future Outlook and Strategic Initiatives - The company plans to further strengthen "Su Ling" product sustainability and expand market advantages [3] - The company is exploring the extension of "Su Ling" into the pet market, with a new drug application for canine hemocoagulase submitted in early July [4] - The company aims to accelerate the development of unmet clinical needs and high-market-potential indications for KC1036 [4] - A new equity incentive plan has been introduced to align with the company's ten-year strategic goals and motivate key personnel [5][6] Investor Relations - The investor relations meeting was held on August 1, 2023, via Tencent Meeting, with participation from major institutional investors [2][7][8]